Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
- 487 Downloads
BPC 157, a pentadecapeptide with extensive healing effects, has recently been suggested to contribute to angiogenesis. However, the underlying mechanism is not yet clear. The present study aimed to explore the potential therapeutic effect and pro-angiogenic mechanism of BPC 157. As demonstrated by the chick chorioallantoic membrane (CAM) assay and endothelial tube formation assay, BPC 157 could increase the vessel density both in vivo and in vitro, respectively. BPC 157 could also accelerate the recovery of blood flow in the ischemic muscle of the rat hind limb as detected by laser Doppler scanning, indicating the promotion of angiogenesis. Histological analysis of the hind limb muscle confirmed the increased number of vessels and the enhanced vascular expression of vascular endothelial growth factor receptor 2 (VEGFR2) in rat with BPC 157 treatment. In vitro study using human vascular endothelial cells further confirmed the increased mRNA and protein expressions of VEGFR2 but not VEGF-A by BPC 157. In addition, BPC 157 could promote VEGFR2 internalization in vascular endothelial cells which was blocked in the presence of dynasore, an inhibitor of endocytosis. BPC 157 time dependently activated the VEGFR2-Akt-eNOS signaling pathway which could also be suppressed by dynasore. The increase of endothelial tube formation induced by BPC 157 was also inhibited by dynasore. This study demonstrates the pro-angiogenic effects of BPC 157 that is associated with the increased expression, internalization of VEGFR2, and the activation of VEGFR2-Akt-eNOS signaling pathway. BPC 157 promotes angiogenesis in CAM assay and tube formation assay. BPC 157 accelerates the blood flow recovery and vessel number in rats with hind limb ischemia. BPC 157 up-regulates VEGFR2 expression in rats with hind limb ischemia and endothelial cell culture. BPC 157 promotes VEGFR2 internalization in association with VEGFR2-Akt-eNOS activation.
BPC 157 promotes angiogenesis in CAM assay and tube formation assay.
BPC 157 accelerates the blood flow recovery and vessel number in rats with hind limb ischemia.
BPC 157 up-regulates VEGFR2 expression in rats with hind limb ischemia and endothelial cell culture.
BPC 157 promotes VEGFR2 internalization in association with VEGFR2-Akt-eNOS activation.
KeywordsBPC 157 Angiogenesis CAM assay Tube formation Hind limb ischemia VEGFR2
This work was supported by the Chang Gung Memorial Hospital [Grants CMRPD1A0531, CMRPD1C0231, CMRPG391311, CMRPG3A1131] and the Ministry of Science and Technology, Taiwan [Grant NMRPD181001-3].
Authors responsible for concept and design were MJH, HTL, HYH, YL, and JHSP. Experimental performance: MJH, HTL, HYH, and YL. Technical supports: CNW, YSK, VHSC, and JSW. MJH, HTL, and JHSP were responsible in the analysis and interpretation of data. MJH and JHSP drafted the manuscript. MJH and HTL contribute to this work equally.
Compliance with ethical standards
All procedures complied with the standards for care and use of animal subjects as stated in the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Resources, National Academy of Sciences, Bethesda, MD). The protocols in our animal studies were approved by the Institutional Animal Care and Use Committee of Chang Gung University.
Conflict of interest
The authors declare that they have no competing interests.
- 2.Sikiric P, Petek M, Rucman R, Seiwerth S, Grabarevic Z, Rotkvic I, Turkovic B, Jagic V, Mildner B, Duvnjak M et al (1993) A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 87:313–327CrossRefPubMedGoogle Scholar
- 3.Sikiric P, Seiwerth S, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D (2010) Revised Robert’s cytoprotection and adaptive cytoprotection and stable gastric pentadecapeptide BPC 157. Possible significance and implications for novel mediator. Curr Pharm Des 16:1224–1234CrossRefPubMedGoogle Scholar
- 8.Jopling HM, Odell AF, Pellet-Many C, Latham AM, Frankel P, Sivaprasadarao A, Walker JH, Zachary IC, Ponnambalam S (2014) Endosome-to-plasma membrane recycling of VEGFR2 receptor tyrosine kinase regulates endothelial function and blood vessel formation. Cells 3:363–385CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Holfeld J, Tepekoylu C, Blunder S, Lobenwein D, Kirchmair E, Dietl M, Kozaryn R, Lener D, Theurl M, Paulus P et al (2014) Low energy shock wave therapy induces angiogenesis in acute hind-limb ischemia via VEGF receptor 2 phosphorylation. PLoS One 9:e103982. doi: 10.1371/journal.pone.0103982 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Lovric-Bencic M, Sikiric P, Hanzevacki JS, Seiwerth S, Rogic D, Kusec V, Aralica G, Konjevoda P, Batelja L, Blagaic AB (2004) Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse. J Pharmacol Sci 95:19–26CrossRefPubMedGoogle Scholar
- 16.Prkacin I, Separovic J, Aralicia G, Perovic D, Gjurasin M, Lovric-Bencic M, Stancic-Rokotov D, Staresinic M, Anic T, Mikus D et al (2001) Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol Paris 95:315–324CrossRefPubMedGoogle Scholar
- 18.Sikiric P, Separovic J, Anic T, Buljat G, Mikus D, Seiwerth S, Grabarevic Z, Stancic-Rokotov D, Pigac B, Hanzevacki M et al (1999) The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J Physiol Paris 93:479–485CrossRefPubMedGoogle Scholar
- 19.Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, Klicek R, Radic B, Keller N, Sipos K et al (2006) Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology 14:214–221CrossRefPubMedGoogle Scholar
- 21.Huang T, Zhang K, Sun L, Xue X, Zhang C, Shu Z, Mu N, Gu J, Zhang W, Wang Y et al (2015) Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug design, development and therapy 9:2485–2499CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V, Turkovic B, Rotkvic I, Mise S, Zoricic I et al (1997) Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol Paris 91:113–122CrossRefPubMedGoogle Scholar
- 27.Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K, Hou X, Nagai Y, Hasegawa M et al (2002) Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ Res 90:966–973CrossRefPubMedGoogle Scholar
- 30.Yasumura EG, Stilhano RS, Samoto VY, Matsumoto PK, de Carvalho LP, Valero Lapchik VB, Han SW (2012) Treatment of mouse limb ischemia with an integrative hypoxia-responsive vector expressing the vascular endothelial growth factor gene. PLoS One 7:e33944. doi: 10.1371/journal.pone.0033944 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ et al (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359:2053–2058CrossRefPubMedGoogle Scholar
- 32.Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E, Committees T, Investigators (2011) Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377:1929–1937CrossRefPubMedGoogle Scholar
- 34.Willmann JK, Chen K, Wang H, Paulmurugan R, Rollins M, Cai W, Wang DS, Chen IY, Gheysens O, Rodriguez-Porcel M et al (2008) Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation 117:915–922CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Imoukhuede PI, Dokun AO, Annex BH, Popel AS (2013) Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia. Am J Phys Heart Circ Phys 304:H1085–H1093Google Scholar
- 37.Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS (2010) VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. Am J Phys Heart Circ Phys 298:H2174–H2191Google Scholar
- 38.Wieczor R, Gadomska G, Ruszkowska-Ciastek B, Stankowska K, Budzynski J, Fabisiak J, Suppan K, Pulkowski G, Rosc D (2015) Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease. J Zhejiang Univ Sci B 16:948–956CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Jeltsch M, Leppanen VM, Saharinen P, Alitalo K (2013) Receptor tyrosine kinase-mediated angiogenesis. Cold Spring Harb Perspect Biol 5. doi: 10.1101/cshperspect.a009183